Mendelian randomization (MR) estimates between accelerometer-based average accelerations and type 2 diabetes and glycemic traits
| Method | No. of SNPs | OR/beta | 95% CI | P value | Outcome |
| Inverse variance weighted (multiplicative random effects) | 7 | 1.00 | (0.94 to 1.07) | 0.948 | Type 2 diabetes |
| Weighted median | 7 | 1.01 | (0.97 to 1.06) | 0.562 | Type 2 diabetes |
| MR-PRESSO: outlier corrected | 4 | 1.03 | (1.01 to 1.06) | 0.103 | Type 2 diabetes |
| MRMix | 7 | 1.52 | (1.14 to 2.03) | 0.004 | Type 2 diabetes |
| Inverse variance weighted (multiplicative random effects) | 5 | 0.001 | (-0.007 to 0.01) | 0.767 | HbA1c |
| Weighted median | 5 | 0.000 | (−0.01 to 0.01) | 0.968 | HbA1c |
| MR-PRESSO: raw | 5 | 0.001 | (−0.007 to 0.01) | 0.782 | HbA1c |
| MRMix | 5 | 0.035 | (−0.917 to 0.987) | 0.943 | HbA1c |
| Inverse variance weighted (multiplicative random effects) | 5 | −0.001 | (−0.017 to 0.015) | 0.914 | Fasting glucose |
| Weighted median | 5 | 0.002 | (−0.019 to 0.023) | 0.861 | Fasting glucose |
| MR-PRESSO: raw | 5 | −0.001 | (−0.012 to 0.01) | 0.886 | Fasting glucose |
| MRMix | 5 | −0.010 | (−0.204 to 0.184) | 0.919 | Fasting glucose |
| Inverse variance weighted (multiplicative random effects) | 5 | −0.002 | (−0.021 to 0.017) | 0.811 | HOMA-B |
| Weighted median | 5 | −0.010 | (−0.03 to 0.009) | 0.294 | HOMA-B |
| MR-PRESSO: raw | 5 | −0.002 | (−0.021 to 0.017) | 0.822 | HOMA-B |
| MRMix | 5 | −0.360 | (−0.698 to −0.022) | 0.037 | HOMA-B |
| Inverse variance weighted (multiplicative random effects) | 5 | −0.001 | (−0.019 to 0.016) | 0.871 | HOMA-IR |
| Weighted median | 5 | −0.003 | (−0.026 to 0.02) | 0.786 | HOMA-IR |
| MR-PRESSO: raw | 5 | −0.001 | (−0.018 to 0.015) | 0.875 | HOMA-IR |
| MRMix | 5 | −0.010 | (−0.269 to 0.249) | 0.940 | HOMA-IR |
HbA1c, hemoglobin A1c; HOMA-B, homeostasis model assessment of beta-cell function; HOMA-IR, homeostasis model assessment of insulin resistance ; MR-PRESSO, MR-Pleiotropy RESidual Sum and Outlier; SNPs, single nucleotide polymorphisms.